Valued editorial board member Jeffrey Cummings (University of Nevada, Las Vegas [UNLV], and Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) shares exciting insights from the session he co-chaired at AAIC20 entitled ‘Microbiome in Alzheimer’s Disease: Pathogenesis and Treatment Implications’.
1. Could you give us a brief overview of the role of the innate immune system in the progression of Alzheimer’s disease (AD)? (0:06)
2. What is known about the impact of alterations in the gut microbiota composition on neuroinflammation? (0:58)
3. What possible mechanisms may underlie the effect of the gut microbiome on the pathogenesis of AD? (1:40)
4. Could you tell us a little about GV-971, its mechanism of action and its clinical development to date? (2:11)
Disclosures: Prof. Cummings has provided consultation to Acadia, Actinogen, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, Cassava, Cerecin, Cerevel, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Karuna, Merck, Novo Nordisk, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant Health, Suven and United Neuroscience pharmaceutical and assessment companies. Prof. Cummings has stock options in Adamas, AnnovisBio, BiOasis and MedAvante. Prof. Cummings owns the copyright of the Neuropsychiatric Inventory. Prof. Cummings is supported by Keep Memory Alive (KMA); NIGMS grant P20GM109025; NINDS grant U01NS093334 and NIA grant R01AG053798.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the Alzheimer’s Association International Conference (AAIC) 2020.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Michael Weiner, AD/PD 2021: The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
It was a great pleasure to meet with Michael Weiner (University of California, San Francisco, CA, USA), the Principal Investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), to discuss the initiative’s aims, design and future developments. The abstract entitled ‘Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)’ was […]
Marwan Sabbagh, AD/PD 2021: Phase 2 MCLENA-1 Trial
touchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment […]
Ivana Rosenzweig, Sleep and Breathing 2021: The Link Between Sleep Apnoea and Dementia
We were delighted to speak with Dr Ivana Rosenzweig (Sleep and Brain Plasticity Centre, King’s College London, London, UK) around her talk on the ‘Link between sleep apnoea and dementia: the neuroimaging perspective‘, which was presented at the virtual 2021 Sleep and Breathing Conference, 16-17 April, 2021. Questions What is known about the relationship between […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!